Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata available, the University of Miami Reproductive and Fertility Center received an FDA Warning Letter on December 3, 2018, regarding biologic products or biologics-related activities. Without access to the full letter text or specific subject line details, the exact nature of the violations cannot be determined from the metadata provided. The warning was issued under FDA's biologics regulatory authority, which typically covers human cells, tissues, and cellular/tissue-based products used in reproductive medicine. Additional documentation would be needed to identify the specific compliance concerns that prompted this enforcement action.